170 related articles for article (PubMed ID: 34031188)
1. TP53 Null Mutations Identify Lung Cancer Cell Lines with Highest Sensitivity to the Nontaxane Microtubule Inhibitor Eribulin.
Hinz TK; Kalkur R; Rabinovitch J; Hinkle W; Heasley LE
Mol Pharmacol; 2021 Aug; 100(2):144-154. PubMed ID: 34031188
[TBL] [Abstract][Full Text] [Related]
2. Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer.
Scarpace SL
Clin Ther; 2012 Jul; 34(7):1467-73. PubMed ID: 22739019
[TBL] [Abstract][Full Text] [Related]
3. Molecular mode of action and role of TP53 in the sensitivity to the novel epothilone sagopilone (ZK-EPO) in A549 non-small cell lung cancer cells.
Winsel S; Sommer A; Eschenbrenner J; Mittelstaedt K; Klar U; Hammer S; Hoffmann J
PLoS One; 2011 Apr; 6(4):e19273. PubMed ID: 21559393
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiling reveals epithelial mesenchymal transition (EMT) genes can selectively differentiate eribulin sensitive breast cancer cells.
Dezső Z; Oestreicher J; Weaver A; Santiago S; Agoulnik S; Chow J; Oda Y; Funahashi Y
PLoS One; 2014; 9(8):e106131. PubMed ID: 25171249
[TBL] [Abstract][Full Text] [Related]
5. Eribulin in non-small cell lung cancer: challenges and potential strategies.
Swami U; Shah U; Goel S
Expert Opin Investig Drugs; 2017 Apr; 26(4):495-508. PubMed ID: 28161993
[TBL] [Abstract][Full Text] [Related]
6. Eribulin mesylate-induced c-Fos upregulation enhances cell survival in breast cancer cell lines.
Tanaka S; Ishii T; Sato F; Toi M; Itou J
Biochem Biophys Res Commun; 2020 May; 526(1):154-157. PubMed ID: 32201082
[TBL] [Abstract][Full Text] [Related]
7. Antitumor and anticancer stem cell activities of eribulin mesylate and antiestrogens in breast cancer cells.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Moriya T
Breast Cancer; 2016 May; 23(3):425-36. PubMed ID: 25552385
[TBL] [Abstract][Full Text] [Related]
8. miR-195 potentiates the efficacy of microtubule-targeting agents in non-small cell lung cancer.
Yu X; Zhang Y; Ma X; Pertsemlidis A
Cancer Lett; 2018 Jul; 427():85-93. PubMed ID: 29656007
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effects of iron depletion plus eribulin on the breast cancer microenvironment.
Goto W; Kashiwagi S; Asano Y; Takada K; Morisaki T; Takahashi K; Fujita H; Shibutani M; Amano R; Takashima T; Tomita S; Hirakawa K; Ohira M
BMC Cancer; 2020 Dec; 20(1):1215. PubMed ID: 33302911
[TBL] [Abstract][Full Text] [Related]
10. ABCB1 and ABCC11 confer resistance to eribulin in breast cancer cell lines.
Oba T; Izumi H; Ito KI
Oncotarget; 2016 Oct; 7(43):70011-70027. PubMed ID: 27588398
[TBL] [Abstract][Full Text] [Related]
11. Eribulin inhibits the growth of small cell lung cancer cell lines alone and with radiotherapy.
Helfrich BA; Gao D; Bunn PA
Lung Cancer; 2018 Apr; 118():148-154. PubMed ID: 29571994
[TBL] [Abstract][Full Text] [Related]
12. Eribulin sensitizes oral squamous cell carcinoma cells to cetuximab via induction of mesenchymal-to-epithelial transition.
Kitahara H; Hirai M; Kato K; Bou-Gharios G; Nakamura H; Kawashiri S
Oncol Rep; 2016 Dec; 36(6):3139-3144. PubMed ID: 27779690
[TBL] [Abstract][Full Text] [Related]
13. TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep).
Cheng LL; Itahana Y; Lei ZD; Chia NY; Wu Y; Yu Y; Zhang SL; Thike AA; Pandey A; Rozen S; Voorhoeve PM; Yu Q; Tan PH; Bay BH; Itahana K; Tan P
Clin Cancer Res; 2012 Aug; 18(15):4201-12. PubMed ID: 22675170
[TBL] [Abstract][Full Text] [Related]
14. Antimitotic and Non-mitotic Effects of Eribulin Mesilate in Soft Tissue Sarcoma.
Kawano S; Asano M; Adachi Y; Matsui J
Anticancer Res; 2016 Apr; 36(4):1553-61. PubMed ID: 27069131
[TBL] [Abstract][Full Text] [Related]
15. Eribulin mesylate.
Jain S; Vahdat LT
Clin Cancer Res; 2011 Nov; 17(21):6615-22. PubMed ID: 21859830
[TBL] [Abstract][Full Text] [Related]
16. Identification of a highly lethal V3
Christopoulos P; Kirchner M; Bozorgmehr F; Endris V; Elsayed M; Budczies J; Ristau J; Penzel R; Herth FJ; Heussel CP; Eichhorn M; Muley T; Meister M; Fischer JR; Rieken S; Lasitschka F; Bischoff H; Sotillo R; Schirmacher P; Thomas M; Stenzinger A
Int J Cancer; 2019 Jan; 144(1):190-199. PubMed ID: 30255938
[TBL] [Abstract][Full Text] [Related]
17. Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK-rearranged non-small-cell lung cancer.
Song P; Zhang F; Li Y; Yang G; Li W; Ying J; Gao S
Cancer Med; 2019 Apr; 8(4):1551-1557. PubMed ID: 30843662
[TBL] [Abstract][Full Text] [Related]
18. Stathmin dynamics modulate the activity of eribulin in breast cancer cells.
Yoshie M; Ishida A; Ohashi H; Nakachi N; Azumi M; Tamura K
Pharmacol Res Perspect; 2021 Aug; 9(4):e00786. PubMed ID: 34176226
[TBL] [Abstract][Full Text] [Related]
19. Combination of Eribulin and Aurora A Inhibitor MLN8237 Prevents Metastatic Colonization and Induces Cytotoxic Autophagy in Breast Cancer.
Kozyreva VK; Kiseleva AA; Ice RJ; Jones BC; Loskutov YV; Matalkah F; Smolkin MB; Marinak K; Livengood RH; Salkeni MA; Wen S; Hazard HW; Layne GP; Walsh CM; Cantrell PS; Kilby GW; Mahavadi S; Shah N; Pugacheva EN
Mol Cancer Ther; 2016 Aug; 15(8):1809-22. PubMed ID: 27235164
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
Qin K; Hou H; Liang Y; Zhang X
BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
